Skip to content

Ketamine: all studies

Page 143 of 449: studies 1,421 to 1,430 of 4,486, newest first. Back to the ketamine overview

Research

A Comparison of the Efficacy and Adverse Effects of Ketamine and Electroconvulsive Therapy in the Management of Treatment-Resistant Depression: A Systematic Review.

Cureus March 1, 2024 Shaan I Chaudhri, Amina Amin, Binay K Panjiyar et al. 2 citations

Ketamine has been repeatedly demonstrated to be an effective treatment in the management of patients with treatment-resistant depression (TRD). An important question is whether it is equally or more effective than the current gold standard of electroconvulsive therapy (ECT), as the adverse effects of ECT can lead to memory loss and neurocognitive deficits. A literature search was conducted for...

DOI: 10.7759/cureus.55596 (opens in new tab) Full text (opens in new tab) Treatment of trd Treatment-resistant depression trd Therapy-resistant depression Refractory depression +4

Ketamine in Substance Use Disorder Treatment: A Narrative Review.

Alpha psychiatry March 1, 2024 Anna Famuła, Jakub Radoszewski, Tomasz Czerwiec et al. 8 citations

Substance use disorder (SUD) continues to pose a significant global health challenge, necessitating innovative and effective therapeutic interventions. Ketamine, traditionally recognized for its anesthetic properties, has emerged as a novel and promising avenue for the treatment of SUD. This narrative review critically examines the current body of literature surrounding the use of ketamine in...

DOI: 10.5152/alphapsychiatry.2024.241522 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Alcohol dependence Addiction treatment Substance abuse recovery +1

Ketamine's rapid and sustained antidepressant effects are driven by distinct mechanisms.

Cellular and Molecular Life Sciences February 27, 2024 Radhika Rawat, Elif Tunc-Ozcan, Sara Dunlop et al. 17 citations

Administration of multiple subanesthetic doses of ketamine increases the duration of antidepressant effects relative to a single ketamine dose, but the mechanisms mediating this sustained effect are unclear. Here, we demonstrate that ketamine's rapid and sustained effects on affective behavior are mediated by separate and temporally distinct mechanisms. The rapid effects of a single dose of...

Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?

European Archives of Psychiatry and Clinical Neuroscience February 27, 2024 Kenji Hashimoto 51 citations

Abstract The growing interest in the rapid and sustained antidepressant effects of the dissociative anesthetic ketamine and classic psychedelics, such as psilocybin, is remarkable. However, both ketamine and psychedelics are known to induce acute mystical experiences; ketamine can cause dissociative symptoms such as out-of-body experience, while psychedelics typically bring about hallucinogenic...

Neurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine.

Translational Psychiatry February 24, 2024 Rachael Sumner, Rebecca McMillan, Anna Forsyth et al. 7 citations

Revealing the acute cortical pharmacodynamics of an antidepressant dose of ketamine in humans with depression is key to determining the specific mechanism(s) of action for alleviating symptoms. While the downstream effects are characterised by increases in plasticity and reductions in depressive symptoms-it is the acute response in the brain that triggers this cascade of events. Computational...

DOI: 10.1038/s41398-024-02738-w (opens in new tab) Full text (opens in new tab) Depression treatment Ketamine therapy Brain connectivity Psychopharmacology

Hippocampal volume changes after (R,S)-ketamine administration in patients with major depressive disorder and healthy volunteers.

Scientific Reports February 24, 2024 Jennifer W. Evans, Morgan C Graves, Allison C. Nugent et al. 9 citations

The hippocampus and amygdala have been implicated in the pathophysiology and treatment of major depressive disorder (MDD). Preclinical models suggest that stress-related changes in these regions can be reversed by antidepressants, including ketamine. Clinical studies have identified reduced volumes in MDD that are thought to be potentiated by early life stress and worsened by repeated...

The endogenous opioid system in the medial prefrontal cortex mediates ketamine's antidepressant-like actions.

Translational Psychiatry February 12, 2024 Cheng Jiang, Ralph Dileone, Christopher Pittenger et al. 37 citations

Recent studies have implicated the endogenous opioid system in the antidepressant actions of ketamine, but the underlying mechanisms remain unclear. We used a combination of pharmacological, behavioral, and molecular approaches in rats to test the contribution of the prefrontal endogenous opioid system to the antidepressant-like effects of a single dose of ketamine. Both the behavioral actions...

Microdosing ketamine in Drosophila does not block serotonin reuptake, but causes complex behavioral changes mediated by glutamate and serotonin receptors

Journal of Neurochemistry February 7, 2024 Kelly E. Dunham, Kani H. Khaled, Leah Weizman et al.

Microdosing ketamine is a novel antidepressant for treatment‐resistant depression. Traditional antidepressants, like selective serotonin reuptake inhibitors (SSRIs), inhibit serotonin reuptake, but it is not clear if ketamine shows a similar mechanism. Here, we tested the effects of feeding ketamine and SSRIs to Drosophila melanogaster larvae, which has a similar serotonin system to mammals and...

Efficacy of esketamine for the treatment of postpartum depression and pain control following cesarean section: a randomized, double-blind, controlled clinical trial

BMC Anesthesiology February 6, 2024 Shurong Li, Zhifang Zhuo, Renwei Li et al.

Background Postpartum depression (PPD) following a cesarean delivery is a frequently seen complication. Despite the prophylactic effects of ketamine, the impact of esketamine on PPD in women undergoing cesarean section remains uncertain. This study aimed to assess the effectiveness of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) in preventing PPD in women...

Anhedonia in bipolar depression treated with ketamine

Bipolar Disorders February 4, 2024 Alina Wilkowska, Mariusz S. Wiglusz, Aleksandra Arciszewska et al. 17 citations

BACKGROUND: Bipolar depression is the major cause of morbidity in patients with bipolar disorder. It affects psychosocial functioning and markedly impairs occupational productivity. Anhedonia is one of the most debilitating symptoms of depression contributing to treatment resistance. It correlates with suicidality, low quality of life, social withdrawal, and poor treatment response. Currently,...

DOI: 10.1111/bdi.13409 (opens in new tab) Ketamine Anhedonia Depression economics Bipolar disorder +3